ITM and Radiopharm sign supply agreement for n.c.a. Lutetium-177

ITM Isotope Technologies Munich SE signed a supply agreement to provide Radiopharm Theranostics with non-carrier-added Lutetium-177 for use in Radiopharm's clinical pipeline of radiopharmaceutical cancer treatments.

“Ensuring supply of key isotopes continues to be a priority for our team, allowing us to accelerate our clinical programs.”itm-radiopharma.com

• 1 source
• itm-radiopharma.comITM Radiopharma: ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177May 19, 2025

Summarized from public sources; check the original articles before acting on it.